Standard BioTools reports Q2 EPS (9c), consensus (4c)

Reports Q2 revenue $21.76M, consensus $39.83M. “The second quarter was a clear demonstration of our strategy in action. Our team delivered another solid quarter of performance, even as U.S. Academic spend remained under pressure, while taking meaningful steps to transform the business,” said Michael Egholm, president and CEO of Standard BioTools (LAB). “The announced sale of SomaLogic to Illumina marks a pivotal milestone in that evolution – unlocking up to $425 million in total cash consideration with additional upside levers and further validating the power of our model.”